Twist Bioscience Corporation (TWST) Stock Analysis

Q: What is the TWST stock price target?

Take-profit $64.74 (+7.9% upside). Prior stop was $55.79.

Q: What are the risks of investing in TWST?

Concentration risk — Supplier: single-source supplier; Target reached (-20.2% upside); Quality below floor (3.0 < 4.0); Target reached (-20.2% upside); Quality below floor (3.0 < 4.0).

Q: Is TWST overvalued or undervalued?

Twist Bioscience Corporation trades at a P/E of N/A (forward -31.0). TrendMatrix value score: 3.4/10. Overall verdict: Sell.

Q: What do analysts say about TWST?

17 analysts cover TWST with a consensus score of 4.2/5. Average price target: $55.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-05-01

Healthcare · Diagnostics & Research

Earnings in 3 days (2026-05-04). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, serving synthetic biology, NGS tools, and biopharma antibody discovery markets. Revenue was $376.6M in fiscal 2025 from 3,800+ customers across healthcare, chemicals/materials, and academic... Read more

$59.94+7.9% A.UpsideScore 4.1/10#24 of 25 Diagnostics & Research

Stop $55.79Target $64.74(resistance)A.R:R -1.4:1

Analyst target$55.00-8.2%9 analysts

$64.74our TP

$59.94price

$55.00mean

$36

$75

Sell if holding. Engine safety override at $59.94: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 31%; Elevated put/call ratio: 9.50; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.1/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 3d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Supplier: single-source supplier

Target reached (-20.2% upside)

Quality below floor (3.0 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-31.0

Mkt Cap$3.6B

EV/EBITDA-31.0

Profit Mgn-19.6%

ROE-16.8%

Rev Growth16.9%

Beta2.21

DividendNone

Rating analysts17

Quality Signals

Piotroski F6/9

Options Flow

P/C9.50bearish

IV107%elevated

Max Pain$35-41.6% vs spot

Concentration Risks(10-K Item 1A)

HIGHSuppliersingle-source supplier
10-K Item 1A: 'We depend on one single-source supplier for a critical component for our DNA synthesis process.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value3.415%0.51

Quality3.015%0.45

Growth6.715%1.00

Momentum4.110%0.41

Sentiment5.810%0.58

Insider Activity3.310%0.33

Peer Rank2.510%0.25

Technical Setup4.95%0.25

Risk Profile1.95%0.10

Catalyst5.25%0.26

Overall (Σ contributions)4.14

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Short Interest

0.4

Beta

2.6

Max Pain Risk

3.0

Debt Equity

9.0

High short interest justified: 31%Elevated put/call: 9.50High IV: 107%Above max pain $35Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.2

Value Rank

2.4

Growth Rank

7.2

Unprofitable operations — net margin -19.6%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

5.0

Gross Margin

6.3

Piotroski F

6.7

Current Ratio

9.2

Cash-burning: FCF -12% of revenueNo competitive moat

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Analyst Target

3.0

4.0

Low model confidence on this dimension (33%).

GatesMomentum 4.1<4.5A.R:R -1.4=NEGATIVEEARNINGS PROXIMITY 3d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

66 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $47.11Resistance $66.06

Price Targets

$56

$65

A.Upside+8.0%

A.R:R-1.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-20.2% upside)

! Quality below floor (3.0 < 4.0)

! Value-trap signals (2/5): Margin compression (op margin -9.4%), Material insider selling (9 sells, 0.05% of cap)

Earnings

3/4 beats

Next Earnings2026-05-04 (3d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is TWST stock a buy right now?

Sell if holding. Engine safety override at $59.94: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 31%; Elevated put/call ratio: 9.50; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $55.79. Score 4.1/10, moderate confidence.

What is the TWST stock price target?

Take-profit target: $64.74 (+7.9% upside). Prior stop was $55.79. Stop-loss: $55.79.

What are the risks of investing in TWST?

Concentration risk — Supplier: single-source supplier; Target reached (-20.2% upside); Quality below floor (3.0 < 4.0).

Is TWST overvalued or undervalued?

Twist Bioscience Corporation trades at a P/E of N/A (forward -31.0). TrendMatrix value score: 3.4/10. Verdict: Sell.

What do analysts say about TWST?

17 analysts cover TWST with a consensus score of 4.2/5. Average price target: $55.

What does Twist Bioscience Corporation do?Twist Bioscience manufactures synthetic DNA using a proprietary silicon chip platform, serving synthetic biology, NGS...